menu
    • menu
    [{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"AmMax Bio","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Undisclosed","year":"2023","type":"Licensing Agreement","leadProduct":"Undisclosed","moa":"Undisclosed","graph1":"Oncology","graph2":"Preclinical","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Preclinical","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Oral","sponsorNew":"Evopoint Biosciences \/ AmMax Bio","highestDevelopmentStatusID":"4","companyTruncated":"Evopoint Biosciences \/ AmMax Bio"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Merck & Co","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"CHINA","productType":"Other Small Molecule","year":"2023","type":"Collaboration","leadProduct":"Pembrolizumab","moa":"||EZH2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":0,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Merck & Co","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Merck & Co"},{"orgOrder":0,"company":"Evopoint Biosciences","sponsor":"Astellas Pharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"GERMANY","productType":"Antibody-drug Conjugate","year":"2025","type":"Licensing Agreement","leadProduct":"XNW27011","moa":"CLDN18.2","graph1":"Oncology","graph2":"Phase I\/ Phase II","graph3":"Evopoint Biosciences","amount2":1.54,"highestDevelopmentShortName":"Ph I\/II","therapeuticAreaShortName":"Oncology","amount2New":1.54,"dosageForm":"Undisclosed","sponsorNew":"Evopoint Biosciences \/ Astellas Pharma","highestDevelopmentStatusID":"7","companyTruncated":"Evopoint Biosciences \/ Astellas Pharma"}]

    Find Clinical Drug Pipeline Developments & Deals by Evopoint Biosciences

    Menu

    Evopoint Biosciences

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Evopoint Biosciences

                            China arrow
                            FCE Pharma
                            Not Confirmed

                            Evopoint Biosciences

                            China arrow
                            FCE Pharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XNW27011

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $1,540.0 million

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            Astellas Licenses XNW27011 from Evopoint Targeting CLDN18.2 in Cancer Therapy

                            Details : The agreement grants Astellas a worldwide exclusive license to develop and commercialize XNW27011, a novel investigational ADC targeting CLDN18.2 for solid tumors.

                            Product Name : XNW27011

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : $130.0 million

                            May 28, 2025

                            Lead Product(s) : XNW27011

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Astellas Pharma

                            Deal Size : $1,540.0 million

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Evopoint Biosciences

                            China arrow
                            FCE Pharma
                            Not Confirmed

                            Evopoint Biosciences

                            China arrow
                            FCE Pharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Study Phase : Preclinical

                            Sponsor : AmMax Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            AmMax Bio Enters into an Exclusive Option Agreement with Evopoint Biosciences to License a Next Generation Ant...

                            Details : Under the terms of agreement, AmMax Bio and Evopoint Biosciences will work together to complete the upcoming IND filing and design subsequent dose-escalating clinical studies for next generation antibody drug conjugate (ADC).

                            Product Name : Undisclosed

                            Product Type : Undisclosed

                            Upfront Cash : Undisclosed

                            September 01, 2023

                            Lead Product(s) : Undisclosed

                            Therapeutic Area : Oncology

                            Highest Development Status : Preclinical

                            Sponsor : AmMax Bio

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Evopoint Biosciences

                            China arrow
                            FCE Pharma
                            Not Confirmed

                            Evopoint Biosciences

                            China arrow
                            FCE Pharma
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : XNW5004,Pembrolizumab

                            Therapeutic Area : Oncology

                            Study Phase : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            DEALS_DEV arrow-down

                            Evopoint Announces Clinical Trial Collaboration Agreement with MSD for the Study of XNW5004 in Combination wit...

                            Details : Under the terms of the agreement, Evopoint will sponsor the Phase Ib/II trial and MSD will supply KEYTRUDA®. Evopoint maintains the global rights to XNW5004. XNW5004 is a rationally designed, highly selective and potent small molecule inhibitor of EZH2.

                            Product Name : XNW5004

                            Product Type : Other Small Molecule

                            Upfront Cash : Undisclosed

                            June 04, 2023

                            Lead Product(s) : XNW5004,Pembrolizumab

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I/ Phase II

                            Sponsor : Merck & Co

                            Deal Size : Undisclosed

                            Deal Type : Collaboration

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth